Stockholders' Equity (Tables)
|
12 Months Ended |
Dec. 31, 2019 |
|---|
| Stockholders' Equity |
|
| Schedule of stock-based compensation expense |
The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted Common Stock awards and warrants for the years ended December 31, 2019 and 2018:
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31,
|
|
($ in thousands)
|
|
2019
|
|
2018
|
|
Employee awards
|
|
$
|
5,094
|
|
$
|
5,940
|
|
Non-employee awards
|
|
|
121
|
|
|
93
|
|
Warrants
|
|
|
97
|
|
|
—
|
|
Partner Companies:
|
|
|
|
|
|
|
|
Avenue
|
|
|
1,839
|
|
|
1,537
|
|
Checkpoint
|
|
|
3,121
|
|
|
1,994
|
|
Mustang
|
|
|
2,664
|
|
|
4,960
|
|
Other
|
|
|
252
|
|
|
488
|
|
Total stock-based compensation expense
|
|
$
|
13,188
|
|
$
|
15,012
|
|
| Share Based Compensation Stock Options, and Other Types of Grants of Stock Option |
The table below provides a summary of those plans as of December 31, 2019:
|
|
|
|
|
|
|
|
|
Partner
|
|
|
|
Shares
|
|
Shares available at
|
|
Company
|
|
Stock Plan
|
|
Authorized
|
|
December 31, 2019
|
|
Aevitas
|
|
Aevitas Therapeutics, Inc. 2018 Long Term Incentive Plan
|
|
2,000,000
|
|
1,702,000
|
|
Avenue
|
|
Avenue Therapeutics, Inc. 2015 Stock Plan
|
|
2,000,000
|
|
405,849
|
|
Baergic
|
|
FBIO Acquisition Corp. III 2017 Incentive Plan
|
|
2,000,000
|
|
2,000,000
|
|
Cellvation
|
|
Cellvation Inc. 2016 Incentive Plan
|
|
2,000,000
|
|
300,000
|
|
Checkpoint
|
|
Checkpoint Therapeutics, Inc. Amended and Restated 2015 Stock Plan
|
|
5,000,000
|
|
1,465,805
|
|
Cyprium
|
|
Cyprium Therapeutics, Inc. 2017 Stock Plan
|
|
2,000,000
|
|
2,000,000
|
|
Helocyte
|
|
DiaVax Biosciences, Inc. 2015 Incentive Plan
|
|
2,000,000
|
|
341,667
|
|
Journey
|
|
Journey Medical Corporation 2015 Stock Plan
|
|
3,000,000
|
|
190,792
|
|
Mustang
|
|
Mustang Bio, Inc. 2016 Incentive Plan
|
|
5,000,000
|
|
1,931,015
|
|
Tamid
|
|
FBIO Acquisition Corp. V 2017 Incentive Plan
|
|
2,000,000
|
|
1,600,000
|
|
| Schedule of Stock option activities |
The following table summarizes Fortress stock option activities excluding activities related to partner companies:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
|
|
|
average
|
|
|
|
|
|
|
|
|
Total weighted
|
|
|
remaining
|
|
|
|
|
|
Weighted average
|
|
average
|
|
|
contractual life
|
|
|
|
Number of shares
|
|
exercise price
|
|
intrinsic value
|
|
|
(years)
|
|
Options vested and expected to vest at December 31, 2017
|
|
1,310,501
|
|
$
|
3.78
|
|
$
|
1,351,080
|
|
|
3.95
|
|
Forfeited
|
|
(25,000)
|
|
|
4.75
|
|
|
—
|
|
|
—
|
|
Options vested and expected to vest at December 31, 2018
|
|
1,285,501
|
|
$
|
3.75
|
|
$
|
—
|
|
|
2.93
|
|
Granted
|
|
125,000
|
|
|
1.18
|
|
|
173,750
|
|
|
|
|
Options vested and expected to vest at December 31, 2019
|
|
1,410,501
|
|
$
|
4.30
|
|
$
|
684,752
|
|
|
2.33
|
|
Options vested and exercisable
|
|
1,310,501
|
|
$
|
4.54
|
|
$
|
545,752
|
|
|
2.20
|
|
| Schedule of Restricted stock awards and restricted stock units |
The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress subsidiaries:
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
|
|
|
|
Number of shares
|
|
grant price
|
|
Unvested balance at December 31, 2017
|
|
11,874,034
|
|
$
|
2.63
|
|
Restricted stock granted
|
|
1,721,802
|
|
|
3.81
|
|
Restricted stock vested
|
|
(213,334)
|
|
|
2.76
|
|
Restricted stock units granted
|
|
490,000
|
|
|
3.64
|
|
Restricted stock units forfeited
|
|
(474,478)
|
|
|
3.94
|
|
Restricted stock units vested
|
|
(752,042)
|
|
|
3.56
|
|
Unvested balance at December 31, 2018
|
|
12,645,982
|
|
$
|
2.72
|
|
Restricted stock granted
|
|
1,546,408
|
|
|
0.88
|
|
Restricted stock forfeited
|
|
—
|
|
|
—
|
|
Restricted stock vested
|
|
(220,000)
|
|
|
3.16
|
|
Restricted stock units granted
|
|
290,000
|
|
|
1.49
|
|
Restricted stock units forfeited
|
|
(135,416)
|
|
|
3.91
|
|
Restricted stock units vested
|
|
(358,960)
|
|
|
3.61
|
|
Unvested balance at December 31, 2019
|
|
13,768,014
|
|
$
|
2.46
|
|
| Schedule of Warrant activities |
The following table summarizes Fortress warrant activities, excluding activities related to partner companies:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
|
|
|
|
|
|
|
|
|
Total weighted
|
|
remaining
|
|
|
|
|
|
Weighted average
|
|
average intrinsic
|
|
contractual life
|
|
|
|
Number of shares
|
|
exercise price
|
|
value
|
|
(years)
|
|
Outstanding as of December 31, 2017
|
|
2,774,189
|
|
$
|
3.30
|
|
$
|
2,204,530
|
|
4.47
|
|
Forfeited
|
|
(20,000)
|
|
|
5.72
|
|
|
—
|
|
—
|
|
Outstanding as of December 31, 2018
|
|
2,754,189
|
|
$
|
3.28
|
|
$
|
—
|
|
3.49
|
|
Granted
|
|
60,000
|
|
|
1.92
|
|
|
39,000
|
|
|
|
Forfeited
|
|
(73,009)
|
|
|
5.65
|
|
|
—
|
|
|
|
Outstanding as of December 31, 2019
|
|
2,741,180
|
|
$
|
3.19
|
|
$
|
111,000
|
|
2.73
|
|
Exercisable as of December 31, 2019
|
|
2,656,180
|
|
$
|
3.22
|
|
$
|
72,000
|
|
2.58
|
|